United European Gastroenterology journal, 2020 Background Type-1 gastric neuroendocrine tumors represent a recurring disease and long-acting somatostatin analogs can inhibit both gastrin release and endocrine cell proliferation. The efficacy and timing of this treatment are still unclear.
R. Rossi +3 more
semanticscholar +1 more source
The pathophysiological consequences of somatostatin receptor internalization and resistance [PDF]
, 2003 Somatostatin receptors expressed on tumor cells form the rationale for somatostatin analog treatment of patients with somatostatin receptor-positive neuroendocrine tumors.
Hofland, L.J. (Leo) +1 more
core +3 more sources
Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]
, 1994 The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S. +7 more
core +1 more source
DISSOCIATION OF BIOCHEMICAL AND TUMOR-SUPRESSIVE EFFECTS OF SOMATOSTATIN ANALOGS
Alʹmanah Kliničeskoj Mediciny, 2016 Normalization of the growth hormone and IGF-1 levels during somatostatin analogs treatment usually is a predictor of somatotropinoma volume reduction.
A. V. Dreval’ +4 more
doaj +1 more source
Treatment options for PNET liver metastases. a systematic review [PDF]
, 2018 Pancreatic neuroendocrine tumors (PNETs) are rare pancreatic neoplasms. About 40-80% of patients with PNET are metastatic at presentation, usually involving the liver (40-93%). Liver metastasis represents the most significant prognostic factor.
Aurello, Paolo +8 more
core +1 more source
Human Pancreas GH-Releasing Factor Analog Restores High-Amplitude GH Pulses in CNS Lesion-Induced GH Deficiency [PDF]
, 1983 Lesions of the ventromedial-arcuate (VMH-ARC) region of the hypothalamus result in impaired growth accompanied by a marked suppression in spontaneous GH secretory bursts. We studied the effects of an analog of the recently characterized human pancreas GH-
Eikelboom, Rudy +2 more
core +2 more sources
Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma
Frontiers in Oncology, 2020 Somatostatin receptor (SSTR) 2, widely expressed in meningioma, is a G-protein-coupled receptor and can be activated by somatostatin or its synthetic analogs.
Wei Wu +7 more
doaj +1 more source
A case of insulinoma with hypoglycemia that was better managed with lanreotide than octreotide
Clinical Case Reports, 2021 Long‐acting somatostatin analogs, including lanreotide slow release (LAN‐SR) and octreotide long‐acting release (OCT‐LAR), can improve hypoglycemia in insulinoma. LAN‐SR may be more beneficial in some patients with insulinoma than OCT‐LAR.
Keiko Yamaoka +14 more
doaj +1 more source
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group [PDF]
, 2019 Purpose: Many different treatments are suggested by guidelines to treat grade 1−2 (G1−G2) neuroendocrine tumors (NET). However, a precise therapeutic algorithm has not yet been established.
Badalamenti, G. +17 more
core +1 more source
Gastroenteropancreatic Neuroendocrine Tumors—Current Status and Advances in Diagnostic Imaging
Diagnostics, 2023 Gastroenteropancreatic neuroendocrine neoplasia (GEP-NEN) is a heterogeneous and complex group of tumors that are often difficult to classify due to their heterogeneity and varying locations.
Daniel Vogele +7 more
doaj +1 more source